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• Nanomedicine has the potential to enhance bioavailability and delivery of low solubility 
compounds to sanctuary sites.  
• Lopinavir (LPV) is a protease inhibitor (PI) with low bioavailability (<2%) that requires 
boosting with ritonavir (RTV).  
• Conversely to current approaches this study uses a ‘bottom up’ process to manufacture 
an impact on the bioavailabilty of LPV by nanoformulation.  
• Oil in water, freeze dried nanoformulation (Fig 1) allows hydrophobic drugs with low 
solubility potential to be dissolved in an oil with a polymer and surfactant.   
• Nanoparticles are formed through freeze drying of this emulsion.   
• On rehydration the nanoparticles do not dissolve, but disperse into water.   
• Altering the excipients enables the modulation of particle characteristics.   
• This study investigates the relationship between particle properties including; size (z-
average), surface charge (zeta potential) and polydispersity on cellular accumulation 
(CAR) and transcellular permeability of LPV dispersions.     
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 Nanoformulation has the ability to increase both LPV accumulation and 
transpermeability. 
 Nanoformulation of LPV has a lesser impact on accumulation of LPV in MDM cell 
line ATHP-1 when compared to other cell lines used in this study. 
 By increasing polydispersity and lowering particle size increases cellular 
accumulation in Caco-2, THP-1, CEM, HepG2. 
 Conversely, lowering polydispersity, and increasing the particle size has the 
potential to increase cellular accumulation in MDM cell line ATHP-1. 
 LPV dispersions surpass the aqueous solution of the drug in crossing the Caco-2 
monolayer during transcellular permeability assays, although certain formulations 
efflux at rate that is lower at the 2 hr time point than at the 1 hr time point.   
 By using a large number of surfactants and polymers, inferring changes in particle 
size, surface charge and polydispersity means that using experimental values from 
cellular accumulation/transpermeability/cytotox etc, models can be derived that aid 
design of nanoparticles with increased biological potential. 
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Fig 1: Method of formulation; Zhang et. al. Nature Nanotechnology 3, 2008, 506 – 511 
• Zhang H, Wang D, Butler R, Campbell NL, Long J, Tan B, Duncalf DJ, Foster AJ, 
Hopkinson A, Taylor D, Angus D, Cooper AI and Rannard SP (2008) Formation and 
enhanced biocidal activity of water-dispersable organic nanoparticles. Nat 
Nanotechnol 3:506-511. 
Cell culture 
All cell lines were propagated in DMEM (HepG2 and Caco-2) or RPMI 1640 (THP-1 and 
CEM). A-THP-1 (monocyte derived macrophages; MDMs) were differentiated from THP-1 
by activation using phorbol 12-myristate 13-acetate (PMA; 100nM) for 7 days. 
Nanoformulations 
74 LPV dispersions containing 0.1 µCi 3H-LPV were generated.  Table 1 details the 
particle properties including median value including; zeta potential (surface charge); z-
average (size range) and polydispersity.  Table 1 also includes the list of surfactants and 
polymers used in creating this bank of dispersions and the frequency of use across the 74 
formulations. 
Cellular Accumulation 
Cells were propagated to a cell density of 5 million cells per assay, using the same cell  
passage for each cell line per experiment.  The cells were washed (x2) in Hanks Balanced 
Salt Solution (HBSS) and incubated with each LPV dispersion (10 µM, formulated with 0.1 
µCi 3H+ LPV).  After 1 hr an an extracellular sample was taken for scintillation counting.  
The cells were then washed in ice cold HBSS (x2) and the cells lysed using 100 µl water.  
The lysate was then taken for quantitation by scintillation counting as an intracellular 
measurement. The extracellular to intracellular comparison of the concentrations of LPV 
present were then used to then calculate a cellular accumulation ratio (CAR). 
Caco-2 transpermeability assay 
A 0.4 µM permeable transwell support (polycarbonate) (Corning, Ltd), was seeded with 
35K Caco-2 cells and propagated on over a 21 day period to form a polarised monolayer 
with tight junctions mimicking the endothelial layer of the gut. The monolayer integrity of 
each well was determined by the level of transepithelial resistance.  Only monolayers with 
values >1000 Ω were used for subsequent experiments.  Apical>basolateral transport was 
measured over a 2hr time period.  Radiolabelled LPV nanoformulation was added to the 
apical chamber at a concentration of 10 µM, containing 3H-LPV as with the cellular 
accumulation. 
Nanoparticle comparison of Cellular Accumulation and Caco-2 transpermeability 
Data were log transformed and models to describe relationships between particle 
properties and biological characteristics were constructed using multiple linear regression.  
Excipients 
Range / number of 
samples 
Zeta Potential median -3.7 (-56.7- 39.7) mV 
Z average median 436 (184-3145) nm 
Polydispersity Median 0.3 (0.1-0.9) 
PVA 12 
Pluronic  F68 7 
Pluronic  F127 10 
Hyamine 12 
CTAB 12 
PEG 1K 5 
Kollicoat 11 
PVP 30K 6 
HPC 4 
HPMC 10 
Hydrolysed Gelatine 6 
NaCMC 3 
Na Alginate 3 
Na Mystriate 1 
Na Deoxycholate 4 
Na Caprylate 5 
Vit E-PEG succinate 6 
Sisterna 11 2 
Sisterna 16 1 
Chremophor 8 
Solution HS 6 
Tween 20 6 
Tween 80 9 
Brij 58 8 
AOT 7 
SDS 1 
Fig 2: Cellular accumulation 
ratio (CAR) of LPV 
nanoformulations across 5 
immortalised cell lines.  The 
red line corresponds to the 
CAR value for the parental 
drug, the green line 
represents the median value 
for the accumulation dataset. Table 1: Nanoparticle properties including; the 
frequency of individual surfactants and 
polymers used in formulation; median value 
and low to high range of zeta-potential, z-
average and polydispersity. 
• Previous work at the University of Liverpool, (data not shown), has identified that 
nanoformulation of LPV reduces the cellular toxicity when compared to aqueous 
solution of the drug.  
• Fig 2 illustrates the Cellular accumulation of the 74 nanoLPV dispersions compared 
to the parental LPV.  Certain dispersions exhibited a higher CAR than the aqueous 
LPV e.g. the median CAR value for nanoLPV in  CEMs was 17.0 with a range of 
values from 2.8-105.1 compared to 13.1 for aqueous LPV. 
• Accumulation assays for each cell line identified formulations with higher LPV 
accumulation.  
• Accumulation of nanoLPV in Caco-2, HepG2 and CEM cells had median CAR 
values greater than the CAR value for the aqueous solution of the drug. 
• Fig 3, uses the LogHepG2 CAR values as an example of how it is possible to 
correlate particle properties to cellular accumulation (CAR) and that modelling can be 
used to  predict CAR in a certain cell lines using particle properties. 
• A Bland and Altman plot in Fig 3E compares the same data set of average 
observed/predicted data to show that most points lie within 2 standard deviations.   
• Data not shown identified that HepG2 (r =-0.38), Caco2 (r = -0.39), THP1 (r = -0.14) 
and CEM (r = -0.09) showed inverse correlation with polydispersity and z-average. 
• Interestingly, in phagocytic ATHP1 cells a direct relationship was evident (r = 0.28).   
• Fig 5, expands on these data, showing prediction of CAR on altering z-average and 
polydispersity where the single line on each chart represents the CAR of the aqueous 
drug solution.  
•Transcellular permeability of LPV was higher for some nano LPV dispersions where 
the median value for A>B permeation across Caco2 monolayer was compared to 2.5 
%/hr for aqueous LPV.  No correlation with particle properties were seen. 
• Interestingly, certain formulations (Fig 5.C) transversed the Caco-2 monoalyer at a 
higher rate within the first hour, but were decreased at the 2 hr time point.  This may 
be due increased ability of the drug to enter/transverse the cell, or may be 
transported as a particle, degraded and effluxed back accross the membrane in its 
aqueous form.  
 
 
 
Fig4: Predicted impact of; z-
average and polydispersity on 
cellular accumulation (CAR) in 5 
cell lines . 
Caco-2 THP-1 
A-THP-1 CEM 
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Fig 3: Linear regression analysis between Log 
CAR values and; Log z-average (A), Log 
polydispersity (B), Log zeta potential(C).  Graph 
(D) linear regression to model predicted Log 
HepG2 CAR against observed Log HepG2 CAR. 
(E) Bland and Altman plot of predicted/observed 
CAR values. 
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Fig 5: (A) Scatter plot of % 
nanoLPV transported across a 
Caco-2 monolayer compared to 
parental LPV (indicated by the 
red line). Graph (B) shows the 
% of all 74 dispersions crossing 
the Caco-2 monolayer over 2 hr 
period. Graph (C) shows a 
subset of dispersions from 
graph (B) where increased 
transport over 1hr which is 
reduced at 2 hr time point. 
Graph (D) shows transport in 
keeping with parental drug.  
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Aims 
The aim of this study was to identify LPV nanoformulation properties which confer lower 
cytotoxicity, enhanced transcellular permeability and accumulation.  
